Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 2, 2023Journal of Clinical InvestigationOpen Access

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

View Full Paper
Ask AI
Bookmark
Share

Authors

FKFeyza Gül Özbay KurtUniversity of MannheimSLSamantha LasserGerman Cancer Research CenterIAIhor ArkhypovHeidelberg University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kurt et al. (2023) studied this question.

synapsesocial.com/papers/6a025d56a28f8b391669b4d8https://doi.org/10.1172/jci170762
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inflammasomes: Emerging Central Players in Cancer Immunology and Immunotherapy2018 · 54 citations
  2. 2Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ2014 · 127 citations
  3. 3Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients2016 · 94 citations
  4. 4The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin2011 · 275 citations
  5. 5Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT2021 · 83 citations